COVID-19 Small Molecule Therapeutics for PrEP
ID: RRPV-RPP-24-03-SmMolType: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEBARDA - ASPR / DAAPPO / BARDA DCMAWASHINGTON, DC, 20515, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH (AN42)

Original Source

https://sam.gov/opp/720ee6444a344d798139134a3f10f7d3/view
Timeline
    Description

    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is seeking proposals for the "COVID-19 Small Molecule Therapeutics for PrEP" initiative. This opportunity invites qualified offerors to submit project proposals via the Rapid Response Partnership Vehicle (RRPV) Consortium, aimed at developing therapeutics for pre-exposure prophylaxis against COVID-19. The initiative is critical in enhancing public health responses and preparedness against the ongoing pandemic. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.

    Point(s) of Contact
    Rebecca Harmon
    rebecca.harmon@ati.org
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    COVID-19 Small Molecule Therapeutics for PrEP
    Currently viewing
    Special Notice
    Similar Opportunities
    RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the development of NextGen Oral Formulation Vaccines for COVID-19 through a Request for Project Proposals (RPP) issued via the Rapid Response Partnership Vehicle (RRPV) Consortium. The primary objective of this solicitation is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, enhancing the understanding of their potential and improving COVID-19 solutions to bolster preparedness against future health security threats. This initiative is critical in the ongoing efforts to combat COVID-19 and prepare for similar health crises. Interested parties can access the full RPP and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    RRPV Solicitation Summary: On-Demand Manufacturing
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR) through the Biomedical Advanced Research and Development Authority (BARDA), is seeking proposals for the "On-Demand Manufacturing" initiative under the Rapid Response Partnership Vehicle (RRPV) Consortium. The objective of this solicitation is to advance manufacturing technologies that enhance access and enable the rapid, cost-effective, and flexible production of vaccines and other biologics through decentralized manufacturing strategies. This initiative is crucial for improving the responsiveness of the healthcare system in times of need, particularly in the context of public health emergencies. Interested parties can find more information and access the full Request for Project Proposals (RPP) at the RRPV website, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability" through a Special Notice. The objective of this procurement is to establish a long-term partnership focused on developing a flexible and rapid response capability for vaccine development against pandemic influenza and other priority pathogens, initially emphasizing influenza mRNA vaccine development. This initiative is critical for enhancing the nation's preparedness and response to emerging infectious diseases, ensuring readiness to pivot quickly in the face of public health threats. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    Solicitation HEALTH AND HUMAN SERVICES, DEPARTMENT OF Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) is seeking proposals for various health research and development services. This opportunity is typically used for experimental development and healthcare services. The place of performance is in the USA. For more information, please contact BARDA-BAA@hhs.gov. The deadline for proposal submission is September 25, 2028, at 4:30 PM Eastern Time.
    A--Request for Proposals - Phase I Clinical Trials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Phase I clinical trials aimed at developing small molecule and biologics therapeutics, as outlined in RFP No. 75N95024R00086. The selected contractor will be responsible for comprehensive services including protocol development, trial management, and reporting to regulatory agencies, with a focus on safety, tolerability, and pharmacokinetics of the investigational therapeutics. This initiative is crucial for advancing therapeutic development in the field of neurology, ensuring compliance with FDA and ICH GCP standards throughout the trial process. Proposals are due by October 3, 2024, with a contract performance period from April 1, 2025, to March 31, 2035, and a maximum contract value of $233,227,446. Interested parties can contact Evan C. Feely at evan.feely@nih.gov or +1 301 827 5301 for further information.
    Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation
    Active
    Health And Human Services, Department Of
    Solicitation HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking partnerships with organizations providing decentralized healthcare services or Clinical Research Organizations (CROs) with decentralized capabilities. The Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program aims to establish a strong decentralized clinical research capability to support medical countermeasure development and utility.
    DRAFT Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) exploration topic. This initiative aims to enhance access to curative cell therapies for pediatric patients with rare genetic diseases by developing novel quality assurance mechanisms at Academic Medical Centers (AMCs) over a structured 24-month program. The program will focus on identifying manufacturing variability, improving batch quality through signature identification methodologies, and creating statistical tools to guide production decisions, ultimately streamlining the development of small batch autologous cell therapies. Proposals are due by October 22, 2024, and interested parties should direct inquiries to the designated email address provided in the solicitation.
    BARDA DRIVe EZ-BAA-22-100-SOL-00003
    Active
    Health And Human Services, Department Of
    Solicitation: HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking proposals for BARDA DRIVe EZ-BAA-22-100-SOL-00003. This procurement is for health research and development services, health care services, and experimental development. The announcement serves as a reissuance of the BARDA DRIVe EZ-BAA and supersedes prior iterations. For more information, please visit https://drive.hhs.gov/.
    HEalth care Rewards to Achieve Improved OutcomES (HEROES)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the HEalth care Rewards to Achieve Improved OutcomES (HEROES) program, aimed at enhancing community health outcomes via innovative, community-based interventions. This initiative seeks to implement a payment model that incentivizes positive health outcomes across four critical areas: maternal health, heart attack and stroke risk, opioid overdose, and alcohol-related health harms, particularly in underserved populations. The program is significant as it aims to address health disparities and improve public health metrics while reducing the overall healthcare burden. With a total funding amount of $99 million available over three years, interested parties must submit their Solution Summaries by the specified deadlines, with full proposals due in November 2024. For further inquiries, proposers can access the ARPA-H Ask-A-Question platform for technical or administrative questions.
    Pegfilgrastim with VMI
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking proposals for the procurement of Pegfilgrastim 6MG/.06ML (inj, soln, syr, or autoinjector) along with vendor-managed inventory (VMI) services to support national preparedness against public health emergencies. The contract will span five years, including a one-year base period and four optional ordering periods, with an initial quantity of 18,300 units projected to increase based on public health needs. This procurement is critical for maintaining robust health security capabilities and ensuring efficient supply chain management for essential pharmaceuticals. Interested contractors should direct inquiries to LaMonica Norwood at OSContracting@hhs.gov, with proposals due by the specified deadlines outlined in the RFP documentation.